Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BOM:532039's Gross Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 48.54 * Ranked among companies with meaningful Gross Margin % only.
Zenotech Laboratories had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Zenotech Laboratories was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Zenotech Laboratories had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Zenotech Laboratories Gross Margin % Related Terms
Zenotech Laboratories Gross Margin % Historical Data
* Premium members only.
The historical data trend for Zenotech Laboratories's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532039 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zenotech Laboratories's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenotech Laboratories Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenotech Laboratories's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Zenotech Laboratories's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Zenotech Laboratories (BOM:532039) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Zenotech Laboratories and its competitors. According to the industry distribution chart, Zenotech Laboratories ranks #999999 out of 943 companies in the Drug Manufacturers industry.
Is Zenotech Laboratories' Gross Margin % too high?
Zenotech Laboratories' current Gross Margin % is 0.00%. Based on the distribution chart, Zenotech Laboratories ranks #999999 out of 943 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zenotech Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zenotech Laboratories' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zenotech Laboratories ranks #999999 out of 943 companies for Gross Margin %. This places Zenotech Laboratories in the lower half of its industry. The industry median Gross Margin % is 48.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Zenotech Laboratories and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenotech Laboratories's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenotech Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zenotech Laboratories (BOM:532039) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹65.23, compared to a current price of ₹46.40 — trading 28.9% below its estimated fair value. The current Gross Margin % is 0.00%. Zenotech Laboratories' overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Zenotech Laboratories (BOM:532039), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenotech Laboratories (BOM:532039) Overvalued in 2026?
Based on GuruFocus' analysis, Zenotech Laboratories stock appears to be undervalued.
The current stock price of ₹46.40 is trading 28.9% below its estimated GF Value™ of ₹65.23.
GuruFocus considers Zenotech Laboratories to be Modestly Undervalued.
Key valuation signals for BOM:532039:
Gross Margin %: 0.00%
GF Value™: ₹65.23 vs. price of ₹46.40 (28.9% below fair value)
No single metric tells the full story. See the BOM:532039 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.
74GF Score
Get the complete analysis for BOM:532039
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532039 has been successfully added to your 
